Compare First Citizens BancShares Inc (FCNCA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novartis AG — how do they compare? First Citizens BancShares Inc trades at $2,162.12 (market cap $23.76B), while Novartis AG trades at $152.22 (market cap $287.66B). The key difference: Novartis AG is far larger — about 12.1× First Citizens BancShares Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| FCNCA | NVS | |
|---|---|---|
Market Cap | $23.76B | $287.66B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $168.62 |
52-Week Low | $1.64K | $113.50 |
Dividend Yield | 0.41% | 3.14% |
Enterprise Value | — | $327.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,133.72, up 3.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a trailing P/E of 11.94 and consistent earnings beats, including a Q1 2026 EPS of $44.86 versus $39.56 expected. Recent strategic moves include plans to retire the Silicon Valley Bank brand and expand commercial banking capabilities in Q4 2026.
The outlook is supported by solid profitability with a 24.35% net income margin and a shareholder-friendly dividend. Key risks include margin pressure and credit risk exposure from the legacy SVB portfolio. Analyst consensus is cautious with an 81.82% hold rating, though the consensus price target of $2,320 suggests modest upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
